12:00 AM
 | 
Nov 14, 2005
 |  BioCentury  |  Strategy

Winning through sharing

In Kos Pharmaceuticals Inc., Jerini AG found a partner willing to share marketing rights while helping to finance development, something it said other potential partners were unwilling to do. Thus, Jerini last week granted North American sales and marketing rights to its lead product, Icatibant, to KOSP.

KOSP (Cranbury, N.J.) obtained exclusive rights to Icatibant for hereditary angioedema (HAE), asthma and refractory ascites in liver cirrhosis (RAIL) in the U.S. and Canada, while Jerini retains rights elsewhere. Jerini is responsible for development and approval in HAE, while KOSP will be responsible for development in asthma and RAIL. KOSP will pay Jerini E12 million ($14.2 million) up front and make a E10 million ($11.8 million) equity investment in the company. The partners did not disclose milestones and royalties.

"We can't develop these indications...

Read the full 655 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >